作者
Tina Cascone, William N William Jr, Annikka Weissferdt, Cheuk H Leung, Heather Y Lin, Apar Pataer, Myrna CB Godoy, Brett W Carter, Lorenzo Federico, Alexandre Reuben, Md Abdul Wadud Khan, Hitoshi Dejima, Alejandro Francisco-Cruz, Edwin R Parra, Luisa M Solis, Junya Fujimoto, Hai T Tran, Neda Kalhor, Frank V Fossella, Frank E Mott, Anne S Tsao, George Blumenschein Jr, Xiuning Le, Jianjun Zhang, Ferdinandos Skoulidis, Jonathan M Kurie, Mehmet Altan, Charles Lu, Bonnie S Glisson, Lauren Averett Byers, Yasir Y Elamin, Reza J Mehran, David C Rice, Garrett L Walsh, Wayne L Hofstetter, Jack A Roth, Mara B Antonoff, Humam Kadara, Cara Haymaker, Chantale Bernatchez, Nadim J Ajami, Robert R Jenq, Padmanee Sharma, James P Allison, Andrew Futreal, Jennifer A Wargo, Ignacio I Wistuba, Stephen G Swisher, J Jack Lee, Don L Gibbons, Ara A Vaporciyan, John V Heymach, Boris Sepesi
发表日期
2021/3
期刊
Nature medicine
卷号
27
期号
3
页码范围
504-514
出版商
Nature Publishing Group US
简介
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment in operable NSCLC remain unclear. We report the results of the phase 2 randomized NEOSTAR trial (NCT03158129) of neoadjuvant nivolumab or nivolumab + ipilimumab followed by surgery in 44 patients with operable NSCLC, using major pathologic response (MPR) as the primary endpoint. The MPR rate for each treatment arm was tested against historical controls of neoadjuvant chemotherapy. The nivolumab + ipilimumab arm met the prespecified primary endpoint threshold of 6 MPRs in 21 patients, achieving a 38% MPR rate (8/21). We observed a 22% MPR rate (5/23) in the nivolumab arm. In 37 patients resected on trial, nivolumab and nivolumab + ipilimumab produced MPR rates of 24% (5/21) and 50% (8/16 …
学术搜索中的文章
T Cascone, WN William Jr, A Weissferdt, CH Leung… - Nature medicine, 2021